Venous thromboembolism: diagnosis and management of deep venous thrombosis

Wai Khoon Ho, Graeme J Hankey, Cindy H Lee and John W Eikelboom
Med J Aust 2005; 182 (9): 476-481.


  • Venous thromboembolism (VTE) affects 1–2 per 1000 people in the general population each year.

  • Clinical diagnosis of deep venous thrombosis (DVT) is unreliable, and must be confirmed by compression ultrasonography or venography.

  • A low clinical pretest probability of DVT and negative D-dimer result reliably exclude the diagnosis, with no need for diagnostic imaging.

  • Initial treatment of DVT is with low-molecular-weight heparin or unfractionated heparin for at least 5 days, followed by warfarin (target INR, 2.0–3.0) for at least 3 months.

  • A vena cava filter is indicated in patients who are ineligible for anticoagulant therapy or who experience embolism despite therapeutic anticoagulation.

  • Thrombolysis or surgical embolectomy may be used as a limb-saving measure in patients with extensive proximal DVT and circulatory compromise that threatens the viability of the leg.

  • Decisions regarding the optimal duration of anticoagulation to prevent recurrent VTE should be individualised and balance the risk of recurrence if warfarin is stopped against the risk of major bleeding and inconvenience of continuing treatment.

  • The risk of recurrence is highest in people with recurrent unprovoked DVT or chronic predisposing factors (eg, cancer) who require indefinite anticoagulant treatment.

Please login with your free MJA account to view this article in full

  • Wai Khoon Ho1
  • Graeme J Hankey2
  • Cindy H Lee3
  • John W Eikelboom4

  • 1 Royal Perth Hospital, Perth, WA.
  • 2 Department of Medicine, McMaster University, Hamilton, Ontario, Canada.


  • 1. Oger E. Incidence of venous thromboembolism: a community-based study in western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000; 83: 657-660.
  • 2. Lee CH, Hankey GJ, Ho WK, Eikelboom JW. Venous thromboembolism: diagnosis and management of pulmonary embolism. Med J Aust 2005; 182. In press.
  • 3. Heit JA, O’Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162: 1245-1248.
  • 4. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S.
  • 5. Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107: I22-I30.
  • 6. Nielsen HK, Husted SE, Krusell LR, et al. Anticoagulant therapy in deep venous thrombosis: a randomized controlled study. Thromb Res 1994; 73: 215-226.
  • 7. Partsch H, Oburger K, Mostbeck A, et al. Frequency of pulmonary embolism in ambulant patients with pelvic vein thrombosis: a prospective study. J Vasc Surg 1992; 16: 715-722.
  • 8. Partsch H, Kechavarz B, Mostbeck A, et al. Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin. J Vasc Surg 1996; 24: 774-782.
  • 9. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-858.
  • 10. Killewich LA, Bedford GR, Beach KW, Strandness DE. Spontaneous lysis of deep venous thrombi: rate and outcome. J Vasc Surg 1989; 9: 89-97.
  • 11. Van Ramshorst B, van Bemmelen PS, Hoeneveld H, et al. Thrombus regression in deep venous thrombosis: quantification of spontaneous thrombolysis with duplex scanning. Circulation 1992; 86: 414-419.
  • 12. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-1665.
  • 13. Wells PS, Hirsh J, Anderson DR, et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet 1995; 345: 1326-1330.
  • 14. Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997; 350: 1795-1798.
  • 15. Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003; 349: 1227-1235.
  • 16. Fancher T, White R, Kravitz R. Combined use of rapid D-dimer testing and estimation of clinical probability in the diagnosis of deep vein thrombosis: systematic review. BMJ 2004; 329: 821-828.
  • 17. Fraser JD, Anderson DR. Deep venous thrombosis: recent advances and optimal investigation with US. Radiology 1999; 211: 9-24.
  • 18. Stevens SM, Elliott CG, Chan KJ, et al. Withholding anticoagulation after a negative result on duplex ultrasonography for suspected symptomatic deep venous thrombosis. Ann Intern Med 2004; 140: 985-991.
  • 19. Hirsh J, Lee AY. How we diagnose and treat deep vein thrombosis. Blood 2002; 93: 3102-3110.
  • 20. Michiels JJ, Kasbergen H, Oudega R, et al. Exclusion and diagnosis of deep vein thrombosis in outpatients by sequential noninvasive tools. Int Angiol 2002; 21: 9-19.
  • 21. National Health and Medical Research Council. A guide to the development, implementation and evaluation of clinical practice guidelines. Canberra: NHMRC, 1999.
  • 22. Bates SM, Ginsberg JS. Clinical practice. Treatment of deep vein thrombosis. N Engl J Med 2004; 351: 268-277.
  • 23. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S-203S.
  • 24. Eikelboom J, Baker R. Routine home treatment of deep vein thrombosis is now a reality. BMJ 2001; 322: 1191-1193.
  • 25. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49-56.
  • 26. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260-1264.
  • 27. Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic complications of anticoagulant treatment. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 287S-310S.
  • 28. Kearon C. Long term management of patients after venous thromboembolism. Circulation 2004; 110 (Suppl 1): I10-I18.
  • 29. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204S-233S.
  • 30. Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103: 2453-2460.
  • 31. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
  • 32. Watson LI, Armon MP. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev 2004; 4: CD002783.
  • 33. Streiff MB. Vena caval filters: a comprehensive review. Blood 2000; 95: 3669-3677.
  • 34. Brandjes DP, Büller HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349: 759-762.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.